aod9604 human clinical trials efficacy weight loss AOD-9604 Trial Results & FDA Status (2026) AOD9604 Onset Half Life -

The molecule was developed by the Australian pharmaceutical company Metabolic Pharmaceuticals (in collaboration with Monash University) and advanced through Phase I safety trials and a Phase IIb obesity efficacy trial enrolling approximately 900 participants in total

PMCID: PMC7019700

Conversion to estradiol via aromatase bone health, mood regulation, libido

claims exceeding this threshold will be denied or subject to medical review CPT code 96372 carries a 0-day global period

Reach out today to speak to our team of experienced providers and let The Beauty Lab guide you through the process, ensuring that you look natural, refreshed, and beautiful